Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: Bispecifics poised to enter new era
Decade after first approval, bispecifics on the precipice of going mainstream
BioCentury | Nov 7, 2024
Discovery & Translation
Science Spotlight: Multi-epitope antivirals, metastatic transition, and more
BioCentury’s roundup of translational innovations also includes a study from Amgen and a newco spotlight
BioCentury | May 31, 2024
Finance
Public Equity Report: Insmed, Merus raise combined $1B+ after readouts
Plus: PIPEs help Celcuity, Cargo advance clinical programs
BioCentury | May 24, 2024
Product Development
Clinical Report: Merus data stand out among ASCO highlights
Clinical data released ahead of ASCO from Merus, Caribou, BioNTech and more
BioCentury | Jul 20, 2023
Discovery & Translation
Roche’s Hans Clevers sees organoid biobank as source of patient avatars
As industry increasingly seeks human data early in development, Roche’s Institute of Human Biology aims to validate organoids for preclinical work
BioCentury | Apr 14, 2023
Product Development
April 14 Quick Takes: Merus’ bispecific continues to impress at AACR
Plus: Data for Kinnate’s pan-RAF and latest setback for Alvotech’s biosimilar
BioCentury | Apr 29, 2022
Discovery & Translation
Cleavage resistant, regulatable CARs; plus Repertoire, Merus and more
BioCentury’s roundup of translational news
BioCentury | May 22, 2021
Product Development
New paths for a bispecific road less traveled
Bispecific antibodies targeting two tumor antigens are picking up steam, and their benefits could extend to ADCs
BioCentury | Aug 22, 2020
Translation in Brief
IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 30